Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
68
2

Year Published

2021
2021
2023
2023

Publication Types

Select...
6
1

Relationship

1
6

Authors

Journals

citations
Cited by 37 publications
(71 citation statements)
references
References 31 publications
1
68
2
Order By: Relevance
“…Similar results were reported by Langton et al in a recent systematic review of 2020 in 204 pregnant women with pheochromocytoma (maternal and foetal/neonatal mortalities were 9.0% (18/200) and 14.2% (29/204), respectively) [15]. Table 1 describes maternal and foetal mortality in series of pheochromocytoma and PGLs during pregnancy [14][15][16][17][18][19].…”
Section: Epidemiologysupporting
confidence: 82%
See 1 more Smart Citation
“…Similar results were reported by Langton et al in a recent systematic review of 2020 in 204 pregnant women with pheochromocytoma (maternal and foetal/neonatal mortalities were 9.0% (18/200) and 14.2% (29/204), respectively) [15]. Table 1 describes maternal and foetal mortality in series of pheochromocytoma and PGLs during pregnancy [14][15][16][17][18][19].…”
Section: Epidemiologysupporting
confidence: 82%
“…In these patients, caesarean delivery is preferred, as it appears to carry a lower risk of maternal death than vaginal delivery [7,10], although the latter could be considered in selected patients previously treated [10]. In this way, a recent systematic review found that the type of delivery was not associated with adverse outcomes (caesarean 78% vs vaginal 22%, P = 0.24), although caesarean section was two times more common than vaginal delivery and usually reserved for patients with a higher degree of catecholamine excess [16]. Management of PGL during pregnancy may require modification of these recommendations depending on the location of the tumour [29] (Fig.…”
Section: Treatmentmentioning
confidence: 99%
“…Furthermore, prospective morphological and biochemical screening in a French series of 156 NF1 patients found a pheochromocytoma prevalence of 7.7% (12 patients), half (n = 6) of whom were secreting, and with only two of them symptomatic ( 81 ). This study and others showing the positive impact of genetic testing on the management and outcome of patients with paraganglioma-pheochromocytoma, and the poor prognosis of PPGL during pregnancy suggest that despite current recommendations, a screening for PPGL, at least before pregnancy, would improve the prognosis of these patients ( 82 85 ).…”
Section: Pheochromocytoma/paraganglioma (Ppgl) In Phakomatosesmentioning
confidence: 71%
“…PPGL in pregnancy is rare, and many times goes unrecognized until later, potentially causing severe fetal and maternal complications of catecholamine excess [ 139 ]. In a recent combined retrospective multi-center study and systematic review of 249 pregnancies in 232 women with PPGL, only 15% of pregnancies were reported in women with known PPGL prior to conceiving [ 140 ]. Around half of the cohort were women discovered with PPGL during the course of pregnancy, and a third were diagnosed with PPGL only after and within 1 year after delivery or miscarriage.…”
Section: Resultsmentioning
confidence: 99%
“…Notably, no complications of catecholamine excess occurred in women with known PPGLs prior to conceiving, despite the higher rate of metastatic disease in this subgroup, possibly due to more intense monitoring during pregnancy, lower degree of catecholamine excess, and optimal management during pregnancy. Unrecognized PPGL (odds ratio of 27), abdominal or pelvic location of PPGL (odds ratio of 11), and severe catecholamine excess of at least 10 times the upper normal limit (odds ratio of 4.7) were associated with adverse outcomes [ 140 ]. Optimal alpha-blockade during pregnancy was associated with fewer complications (odds ratio of 3.6 for absence of alpha-blockade), suggesting that initiation, dose titration and optimal medical management during pregnancy is key in pregnant women with PPGL.…”
Section: Resultsmentioning
confidence: 99%